Serine Endopeptidases

Name
Serine Endopeptidases
Accession Number
DBCAT000067
Description

Any member of the group of ENDOPEPTIDASES containing at the active site a serine residue involved in catalysis.

Drugs
DrugDrug Description
UrokinaseA low molecular weight form of human urokinase used to treat pulmonary embolism and myocardial infarction as well as to clear IV lines.
ReteplaseA purified form of human tissue plasminogen activator used in the emergency treatment of myocardial infarction, ischemic stroke, and pulmonary emboli.
Coagulation factor VIIa Recombinant HumanA form of recombinant human coagulation Factor VII used to treat hemophilia A and B.
FibrinolysinFibrinolysin assists with the healing of minor burns, superficial wounds, ulcers, surgical wounds, and superficial hematomas.
OcriplasminA proteolytic enzyme used to treat symptomatic vitreomacular adhesion by dissolving the protein matrix responsible for the adhesion between the vitreous and macula.
ChymotrypsinA digestive enzyme supplement used as supportive therapy to manage the side effects associated with conventional chemotherapy, radiotherapy, and hormone therapy.
TrypsinA naturally occurring proteolytic enzyme found in the digestive tract of mammals. Used clinically in combination with bromelain and rutosides in the treatment of some inflammatory conditions.
Thrombin alfaA platelet activating factor used to treat minor bleeding.
AlteplaseA recombinant form of human tissue plasminogen activator used in the emergency treatment of myocardial infarction, ischemic stroke, and pulmonary emboli.
AncrodAn anticoagulant purified from the venom of the Malayan pit viper that functions by inactivating circulating plasma fibrinogen. Not currently approved for use or marketed in any country.
ThrombinA coagulation factor used to stop bleeding during surgery.
KallidinogenaseNot Annotated
Coagulation factor XIaCoagulation factor XIa is under investigation in clinical trial NCT01701947 (HEMOLEVEN® Expanded Access Program Prevention of Surgical/Postpartum Hemorrhage Severe Inherited Factor XI Deficiency).
LactoferrinLactoferrin is under investigation in clinical trial NCT03748043 (The Effectiveness of Lactoferrin in Treatment of Iron Deficiency Anemia in Children With Chronic Tonsillitis).
AnistreplaseA form of recombinant human tissue plasminogen activator used in the emergency treatment of myocardial infarction and pulmonary emboli.
TenecteplaseA modified form of recombinant human tissue plasminogen activator used in the emergency treatment of myocardial infarction and pulmonary emboli.
DesmoteplaseInvestigated for use/treatment in cerebral ischemia and strokes.
Talactoferrin alfaInvestigated for use/treatment in adverse effects (chemotherapy), cancer/tumors (unspecified), diabetic foot ulcers, lung cancer, solid tumors, and ulcers.
LanoteplaseInvestigated for use/treatment in myocardial infarction.
AmediplaseInvestigated for use/treatment in myocardial infarction and thrombosis.
BatroxobinNo approved indications. Batroxobin is a defibrongenating agent which has been observed to reduce fibrinogen levels and thus reduce clot risk when used intravenously.
SutilainSutilain was indicated, in the form of an ointment, as a biochemical debridement of second and third-degree burns, incisional traumatic and pyrogenic wounds and ulcers occurring due to peripheral vascular...
Rusalatide acetateChrysalin has been used in trials studying the treatment of Radius Fracture.
VonapanitaseVonapanitase is under investigation for the treatment of Chronic Kidney Disease.
Vatreptacog alfaVatreptacog Alfa (Activated) has been used in trials studying the treatment of Haemophilia B, Haemophilia A, Congenital Bleeding Disorder, Haemophilia A With Inhibitors, and Haemophilia B With Inhibitors.
MonteplaseMonteplase has been used in trials studying the treatment of Pulmonary Embolism.
SaruplaseNot Annotated
Andexanet alfaA recombinant Factor Xa used to reverse anticoagulation caused by rivaroxaban and apixaban.
Marzeptacog alfa (activated)Marzeptacog alfa (activated) is under investigation in clinical trial NCT01439971 (Phase 1 Safety, Pharmacokinetics And Pharmacodynamics Study Of Recombinant Factor VIIa Variant (813d) In Adult Subjects With Hemophilia).
NattokinaseNattokinase is under investigation in clinical trial NCT00749801 (Efficacy and Safety of Geneferm Nattokinase).
Drugs & Drug Targets
DrugTargetType
UrokinaseUrokinase plasminogen activator surface receptortarget
UrokinasePlasminogentarget
UrokinasePlasminogen activator inhibitor 2target
UrokinasePlasminogen activator inhibitor 1target
UrokinasePlasma serine protease inhibitortarget
UrokinaseNidogen-1target
UrokinaseLow-density lipoprotein receptor-related protein 2target
UrokinaseSuppressor of tumorigenicity 14 proteintarget
UrokinaseMacrophage metalloelastaseenzyme
ReteplaseFibrinogen alpha chaintarget
ReteplasePlasminogentarget
ReteplasePlasminogen activator inhibitor 1target
Coagulation factor VIIa Recombinant HumanCoagulation factor Xtarget
Coagulation factor VIIa Recombinant HumanTissue factortarget
Coagulation factor VIIa Recombinant HumanTissue factor pathway inhibitortarget
Coagulation factor VIIa Recombinant HumanVitamin K-dependent gamma-carboxylasetarget
Coagulation factor VIIa Recombinant HumanCoagulation factor VIItarget
FibrinolysinPlasminogen activator inhibitor 1target
FibrinolysinUrokinase-type plasminogen activatortarget
OcriplasminAlpha-2-macroglobulintarget
OcriplasminAlpha-2-antiplasmintarget
OcriplasminFibronectintarget
Thrombin alfaCoagulation factor VIIItarget
Thrombin alfaCoagulation factor Vtarget
Thrombin alfaFibrinogen alpha chaintarget
Thrombin alfaFibrinogen beta chaintarget
Thrombin alfaFibrinogen gamma chaintarget
AlteplaseFibrinogen alpha chaintarget
AlteplasePlasminogentarget
AlteplasePlasminogen activator inhibitor 1target
AlteplaseFibrinogen gamma chaintarget
AncrodFibrinogen alpha chaintarget
ThrombinProteinase-activated receptor 1target
ThrombinProteinase-activated receptor 4target
ThrombinCoagulation factor XItarget
ThrombinCoagulation factor XIII A chaintarget
ThrombinCoagulation factor XIII B chaintarget
ThrombinFibrinogen alpha chaintarget
ThrombinFibrinogen beta chaintarget
ThrombinFibrinogen gamma chaintarget
ThrombinCoagulation factor Vtarget
ThrombinCoagulation factor VIIItarget
AnistreplaseFibrinogen alpha chaintarget
AnistreplasePlasminogentarget
AnistreplasePlasminogen activator inhibitor 1target
TenecteplaseUrokinase plasminogen activator surface receptortarget
TenecteplasePlasminogen activator inhibitor 1target
TenecteplaseFibrinogen alpha chaintarget
TenecteplasePlasminogen activator inhibitor 2target
TenecteplaseTetranectintarget
TenecteplaseKeratin, type II cytoskeletal 8target
TenecteplaseAnnexin A2target
TenecteplaseCalreticulintarget
TenecteplaseCalnexintarget
TenecteplaseProlow-density lipoprotein receptor-related protein 1target
TenecteplasePlasminogentarget
DesmoteplasePlasminogentarget
LanoteplaseUrokinase plasminogen activator surface receptortarget
LanoteplaseFibrinogen alpha chaintarget
LanoteplaseKallikrein-1target
LanoteplaseLaminin subunit alpha-5target
LanoteplaseCoagulation factor Xtarget
LanoteplaseFibronectintarget
LanoteplasePlasminogen activator inhibitor 2target
LanoteplaseTetranectintarget
LanoteplaseKeratin, type II cytoskeletal 8target
LanoteplaseAnnexin A2target
LanoteplaseLaminin subunit beta-1target
LanoteplaseLaminin subunit gamma-1target
LanoteplaseLaminin subunit alpha-1target
LanoteplaseCalreticulintarget
LanoteplaseCalnexintarget
LanoteplaseProlow-density lipoprotein receptor-related protein 1target
LanoteplaseLaminin subunit alpha-3target
Andexanet alfaTissue factor pathway inhibitortarget